Hutchmed's shares rose 17% after signing a licensing deal with GSK worth up to $1.295 billion for its experimental cancer drug HMPL-A830. GSK gains exclusive rights outside Mainland China, Hong Kong, Macau, and Taiwan, paying $110 million upfront plus potential milestone payments and royalties. The drug targets KRAS-EGFR tumors and will enter global Phase I trials in late 2026, with Hutchmed leading initial development. This deal marks a major step for Hutchmed's drug platform and expands GSK's oncology portfolio.
GSK plc shows strong progress in its oncology pipeline, highlighted by positive phase 1 results for Mo-Rez in treating platinum-resistant ovarian and endometrial cancers. These promising outcomes support plans for five global pivotal phase 3 trials s...
GSK is forecasted to report a third quarter revenue of £8.82 billion, slightly below consensus, with core earnings per share matching expectations. Weak vaccine sales, particularly Shingrix, are expected to be offset by stronger performance in HIV tr...
The complicated urinary tract infections (cUTI) market is projected to expand steadily through 2036, driven by increasing antimicrobial resistance, higher rates of recurrent and hospital-acquired infections, and more patients with underlying conditio...
